TRIM33 and dermatomyositis: Furthermore, our observation paves the way for JAK inhibitors as a treatment strategy to block type I interferon pathway activation in DM (47), which‐in light of our results‐may be more effective in anti‐Mi‐2+‐ than in anti‐TIF‐1γ+‐ associated DM.